3rd Quarter - Amendment

BIOMET, INC. for BIOMET, INC.

Period 3rd Quarter 2012 Filed Oct 25, 2012 Signed by Millard P. Plumlee, Associate General Counsel, Biomet, Inc.

Official filing
Firm
BIOMET, INC.
Client
BIOMET, INC.
Income
—
Expenses
$170,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 18, 2012 $170,000 Replaced
3rd Quarter - Amendment (this page) Oct 25, 2012 $170,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

H.R. 436 - Protect Medical Innovation act of 2012; S.17-Medical Device Access & Innovation Act; FDA user fees; physician-owned companies; Medicare payment policy; gainsharing; medical device excise tax (ACA).

LobbyistCovered position, as disclosed
WILLIAM C KOLTER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Bills named: H.R. 436 (112th), S. 17 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.